Exogenous Recombinant N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B; ARSB) Inhibits Progression of B16F10 Cutaneous Melanomas and Modulates Cell Signaling
S. Bhattacharyya, I. O-Sullivan, J. Tu, Z. Chen, J. K. Tobacman
This study shows that exogenous ARSB treatment reduces B16F10 melanoma tumor size and improves survival by altering chondroitin sulfate levels and modulating cell signaling pathways.
bioRxiv · May 30, 2023Cancer Biology